



18th PEDIATRIC PHARMACY CONFERENCE & PPAG ANNUAL MEETING

SESSION SCHEDULE & OBJECTIVES

Thursday, September 24, 2009

9:00 am-12:00n Hospital Tour Opportunities – Registration Add-On

12:30 –1:30 pm DKA & HHS
0180-0000-09-100-L01-P
Speaker: Mark Haase, PharmD, Associate Professor of Pharmacy Practice
Texas Tech University School of Pharmacy

By the end of this presentation, participants will be able to:

1. Discover how the pathophysiology of DKA contributes to its clinical presentation.
2. Develop a treatment plan for a patient in DKA.
3. Distinguish HHS from DKA in the areas of pathophysiology, presentation, and management.

1:30-2:30 pm Management of Diabetes, Type I
0180-0000-09-102-L01-P
Speaker: Michelle Condren, PharmD, Associate Professor
University of Oklahoma College of Pharmacy

By the end of this presentation, participants will be able to:

1. Compare the advantages and disadvantages of various insulin regimens.
2. Determine patient-specific factors to consider when selecting an insulin regimen.
3. Given a patient case, design a home insulin regimen for a child with Type I diabetes.

2:30-2:45 pm Break

2:45-3:45 pm Pumps, Pens, & Other Devices
0180-0000-09-103-L01-P
Thomas Parker, PharmD, Assistant Professor
Texas Tech University Health Sciences Center

By the end of this presentation, participants will be able to:

1. Describe the functional parameters of insulin pens, subcutaneous injection ports, continuous glucose monitors and subcutaneous insulin infusion pumps.
2. Determine roles for insulin pens, subcutaneous injection ports, continuous glucose monitors and subcutaneous insulin infusion pumps in the management of diabetes mellitus (DM) in children.
3. Given a patient case, design of adjust an insulin pump regiment for a child with DM.

3:45-4:45 pm Management of Diabetes, Type II
0180-0000-09-104-L01-P
Speaker: Allison Blackmer, PharmD, PGY2-Pediatric Specialty Pharmacy Resident
The University of North Carolina Hospitals

By the end of this presentation, participants will be able to:

1. State the epidemiology and pathophysiology of type 2 diabetes mellitus (T2DM) in the pediatric population.
2. Identify the opinions, barriers, and current practices related to T2DM screening in children.
3. List the challenges of treatment of T2DM in children, assess current therapeutic options, and summarize the literature supporting oral therapies for the treatment of pediatric T2DM.

4:45-5:00 pm Moderator & Planning Committee Meeting

5:00-6:00 pm Keynote Address: National Commission on Children & Disasters
0180-0000-09-105-L04-P
Speaker: Michael Anderson, MD,

By the end of this presentation, participants will be able to:

1. Review basic pediatric resuscitation physiology.
2. Review national pediatric disaster readiness.
3. Present Solutions for Crisis.

6:00-6:30 pm First Annual Fellows Class Recognition

6:30-8:30 pm Opening Network Reception

Friday, September 25, 2009

7:00-8:00 am Current Issues in the Management of Pediatric patients with Cystic Fibrosis:
Update 2009
0180-0000-09-126-L01-P

8:00-9:00 am **Sumner J. Yaffe Lifetime Achievement Award**
0180-0000-09-106-L01-P
Speaker: Steven Spielberg

By the end of this presentation, participants will be able to:

1. Understand current state of pediatric therapeutics.
2. Understand the intersection of pediatric and personalized therapeutics.
3. Envision the future of medicine as impacted by genomics.

9:00-10:00 am Best Practice Awards Presentation

- Improvement or Reversal of Parenteral Nutrition Associated Liver Disease in Six Infants with Short Bowel Syndrome Treated with Enteral Fish Oil
0180-0000-09-127-L04-P
- Blinded Volume Verification in a Pediatric Bar-code Medication Administration System (BCMA) to reduce Wrong-Dose Errors
0180-0000-09-128-L04-P
- Pharmacist Validation of Doses Outside Smart Pump Limits
0180-0000-09-129-L04-P

10:00-10:15 am Break

- 10:15-11:15 am Clinical Lecture I: The Role of Biologics in Pediatric Rheumatology
0180-0000-09-107-L01-P
Speaker: Stephen Spalding
- By the end of this presentation, participants will be able to:
1. Understand that juvenile idiopathic arthritis (JIA) is the most common rheumatic condition in children which requires treatment with a biologic.
 2. Realize the biologics are safe and very effective in the treatment of children with JIA
 3. Gain familiarity with the potential short and long-term side effects associated with the biologics.
- 11:15 am-12:15 pm Clinical Lecture II: Management of Pediatric Chemical Casualties: Are We Prepared?
0180-0000-09-108-L04-P
Speaker: Elora Hilmas, PharmD, Pharmacy Practice Residency Coordinator
Alfred I. DuPont Hospital for Children
- By the end of this presentation, participants will be able to:
1. Identify two risk factors that put pediatric patients at higher risk of toxicity from a chemical release compared to adults.
 2. List two special considerations for the decontamination of children that must be addressed in emergency plans.
 3. Describe two reasons why it is critical to develop an emergency cache at your hospital.
- 10:15 am-12:15 pm Research Workshop: Grant Writing
0180-0000-09-109-L04-P
Speaker: Michael Reed, PharmD, Director of Clinical Pharmacology/Toxicology and the Clinical Research Center
Akron Children's Hospital
- By the end of this presentation, participants will be able to:
1. Describe potential sources for attaining extramural funding for pediatric research.
 2. Explain the main components of a grant application.
 3. Provide strategies for successful grantmanship in pediatrics.
- 10:15 am-12:15 pm Advocacy Workshop: Vancomycin Dosing & Monitoring: Applying the IDSA Guidelines to Pediatric Patients
0180-0000-09-110-L01-P
Speakers: Kristin Klein, PharmD & Jen Giroto, PharmD
- By the end of this presentation, participants will be able to:
1. Describe the issues related to dosing vancomycin appropriately in a variety of pediatric patient populations (e.g. neonates, patients with cystic fibrosis, adolescents).
 2. Describe the issues related to the administration of vancomycin in pediatric patients.
 3. Describe the controversies surrounding the monitoring of vancomycin concentrations in pediatric patients.

10:15 am-12:15 pm Leadership Workshop: Simplifying Leadership Complexities in Pediatric Pharmacy Patient Care
0180-0000-09-111-L04-P
Speaker: John Clark, PharmD, Associate Director of Pharmacy & Residency Program Director (UMHHC) & Clinical Assistant Professor (UMCOP)
University of Michigan Hospital & Health Centers & University of Michigan College of Pharmacy

By the end of this presentation, participants will be able to:

1. Understand the complexities of leadership in a pediatric environment.
2. Be able to convey the complexities of pediatric pharmacy to others.
3. Explain leadership strategies to ensure the best care possible is offered to your patients.

2:00-3:30 pm PKPD
0180-0000-09-112-L01-P
Speaker: Marc Scheetz, PharmD

By the end of this presentation, participants will be able to:

1. List the PK/PD targets for various antimicrobials.
2. Identify limitations of the minimum inhibitory concentration (MIC) as a single surrogate for antimicrobial susceptibility testing.
3. Describe research methodologies for optimizing PK/PD in patients.

2:00-3:30 pm Neuro Workshop/Vaccine Safety
0180-0000-09-113-L01-P
Speakers: Lizbeth Hansen, PharmD, Pediatric Care Specialist
Cleveland Clinic
Johanna Goldfarb, PharmD, Head, Pediatric Infectious Diseases
Cleveland Clinic Children's Hospital

By the end of this presentation, participants will be able to:

1. Examine the literature describing the pharmacokinetics and pharmacodynamics of drugs used concomitantly with therapeutic hypothermia.
2. Discuss clinical examples of these "interactions" and their significance in patient care.
3. Review the history of vaccine development and safety in the U.S.
4. Review data on claims of vaccine side effects and present system in the U.S. for compensation.

2:00-3:30 pm Oncology Workshop
0180-0000-09-114-L01-P
Speaker: William Humphrey, PharmD, Director, Pharmacy Operations
St. Jude Children's Research Hospital

By the end of this presentation, participants will be able to:

1. Describe areas to consider when developing a chemotherapy safety program.
2. Name ways to minimize occupational exposure in preparation and administration of antineoplastic chemotherapy.
3. Identify means for ensuring patient safety with chemotherapy including manual and electronic checks and balances.

3:30-3:45 pm Break

3:45-5:15 pm

Super Session: Adolescent Issues

0180-0000-09-115-L04-P

Speaker: Veenod Chulani, MD, Chief, Division of Adolescent Medicine
Arnold Palmer Hospital for Children

By the end of this presentation, participants will be able to:

1. Discuss adolescent sexuality and the developmental and socio-environmental context which it develops.
2. Describe recent trends in adolescent sexual reproductive health.
3. Discuss the implications of current initiatives to promote adolescent sexual and reproductive health on pediatric pharmacy practice, including emergency contraception provision and expedited partner treatment.

6:00-7:45 pm

Dinner Symposium: What's New with RSV and Palivizumab Usage

0180-0000-09-125-L01-P

Speaker: James Dice, PharmD

By the end of this presentation, participants will be able to:

1. Understand the basics of the epidemiology and pathophysiology of RSV infection.
2. Understand the principles of prevention of RSV infection.
3. Currently FDA approved usage of palivizumab.
4. Be able to contrast/compare the current FDA approved schedule for RSV prophylaxis with palivizumab vs the new AAP recommendations.

7:45-9:30 pm

Exhibition & Dessert Reception

Saturday, September 26, 2009

7:00-8:00 am

Clinical Pearls during Continental Breakfast

Extreme Dosing

0180-0000-09-116-L01-P

Speakers: Pete Johnson, PharmD, Assistant Professor, Department of Pharmacy: Clinical & Administrative Sciences (extreme dosing in overweight/obese children – focus on DVT prophylaxis)
University of Oklahoma College of Pharmacy

William McGhee, PharmD, Clinical Pharmacy Specialist (Extreme Dosing: Case studies in pediatric transplantation)
Children's Hospital of Pittsburgh

By the end of this presentation, participants will be able to:

1. Define the categories for overweight/obesity according to BMI percentiles in children.
2. Describe the pharmacokinetic alterations of enoxaparin in overweight/obese children.
3. Provide Recommendations for enoxaparin dosing in overweight/obese children.
4. To list specific situations where extreme dosing is utilized in pediatric transplant recipients.
5. To list drugs, drug combinations, and doses utilized in extreme dosing situations in pediatric transplant recipients.
6. To contrast the benefits and risks associated with extreme dosing in pediatric transplant recipients.
7. To list monitoring procedures to avoid toxicity and to assess efficacy and outcomes of extreme dosing in pediatric transplant recipients.

| | |
|------------------|---|
| 8:00-9:00 am | <p>Scientific Platform Presentations</p> <ul style="list-style-type: none"> • Comparison of Initial and Final Alprostadil Dose Needed to Maintain Patency of the Ductus ARteriosus: Efficacy of Downward Titration 0180-0000-09-130-L04-P • Efficacy of Bar-code Medication Administration (BCMA) on Errors in a pediatric Medical Surgical Unit 0180-0000-09-131-L04-P • A Survey of Children’s Hospitals on the use of Extemporaneous Liquid Formulations in the Inpatient Setting 0180-0000-09-132-L04-P |
| 9:00-11:30 am | Poster Session |
| 11:30 am-1:00 pm | PPAG Town Hall Lunch |
| 1:00-2:00 pm | <p>Richard A. Helms Excellence in Pediatric Pharmacy Practice Award Interplay Between Pediatric Pharmacy Practice & Research to Influence Patient 0180-0000-09-118-L01-P Speaker: Milap Nahata</p> <p>By the end of this presentation, participants will be able to:</p> <ol style="list-style-type: none"> 1. Describe the process for developing research questions from practice to address clinical challenges in pediatric patients. 2. Identify one example of an interplay among practice, education and research that can improve patient care. 3. List one practice challenge which needs to be addressed through education or research. |
| 2:00-2:15 pm | Research Awards Presentations |
| 2:15-2:30 pm | Break |
| 2:30-3:30 pm | <p>Clinical Lecture I: ECMO 0180-0000-09-119-L01-P Speaker: Brenda Dodson, PharmD, Senior Solution Designer Cerner Corporation</p> <p>By the end of this presentation, participants will be able to:</p> <ol style="list-style-type: none"> 1. Describe the basic mechanics of Extracorporeal Membrane Oxygenation (ECMO). 2. Describe the basic mechanics of Continuous Renal Replacement Therapy (CRRT). 3. Discuss modification of drug therapy based on the effects of extracorporeal circuits. |
| 3:30-4:30 pm | <p>Clinical Lecture II: Infectious Disease – CAMRSA 0180-0000-09-120-L01-P Speaker: Kristin Klein, PharmD, Clinical Assistant Professor and Clinical Pharmacist University of Michigan</p> <p>By the end of this presentation, participants will be able to:</p> <ol style="list-style-type: none"> 1. Describe the difference between hospital-acquired and community-acquired MRSA infections. 2. When given a susceptibility report, be able to select an appropriate antimicrobial agent for a patient with an infection due to community-acquired MRSA. 3. Describe the treatment implications for a patient who has developed Pantone-Valentine leukocidin (PVL) syndrome. |

- 2:30-4:30 pm Research Workshop: Meta-Analysis
0180-0000-09-121-L04-P
Speaker: Craig Coleman, PharmD, Associate Professor
University of Connecticut School of Pharmacy
- By the end of this presentation, participants will be able to:
1. Demonstrate how systematic reviews and meta-analyses can inform clinical and health policy decisions.
 2. Identify and describe the fundamental components of a systematic review and meta-analysis.
 3. Evaluate the quality of a systematic review and meta-analysis.
- 2:30-4:30 pm Advocacy Workshop: Vancomycin Dosing & Monitoring: Applying the IDSA Guidelines to Pediatric Patients
0180-0000-09-110-L01-P
Speakers: Jen Giroto, PharmD & Kathy Pham, PharmD
- By the end of this presentation, participants will be able to:
1. Describe the issues related to dosing vancomycin appropriately in a variety of pediatric patient populations (e.g. neonates, patients with cystic fibrosis, adolescents).
 2. Describe the issues related to the administration of vancomycin in pediatric patients.
 3. Describe the controversies surrounding the monitoring of vancomycin concentrations in pediatric patients.
- 2:30-4:30 pm Leadership Workshop: Pharmacist in ED
0180-0000-09-122-L01-P
Speaker: Christopher Shaffer
- By the end of this presentation, participants will be able to:
1. Identify the key elements that support the business decision to allocate pharmacists to the Emergency Department.
 2. To discuss the role of pharmacists in the Emergency Department.
 3. To discuss current and future clinical programs with pharmacists in the Emergency Department.
- 4:40-5:30 pm Special Interest Group Meetings
- 5:30-6:30 pm Committee Meetings

Sunday, September 27, 2009

- 7:00-8:00 am Clinical Pearls during Continental Breakfast
Narcotics/Sedation/NAS, Etc.
0180-0000-09-123-L01-P
Speakers: Mary Temple, PharmD, Clinical Pharmacist, Neonatology,
Pediatrics and Maternal Medicine
Hillcrest Hospital, A Cleveland Clinic Hospital
- By the end of this presentation, participants will be able to:
1. Provide comparisons between the different agents available for withdrawal.
 2. Discuss the timeline for withdrawal of different agents.
 3. Discuss pathophysiology behind opioid withdrawal.

8:00-9:30 am

PKPD
0180-0000-09-112-L01-P
Speaker: Marc Scheetz, PharmD

By the end of this presentation, participants will be able to:

1. List the PK/PD targets for various antimicrobials.
2. Identify limitations of the minimum inhibitory concentration (MIC) as a single surrogate for antimicrobial susceptibility testing.
3. Describe research methodologies for optimizing PK/PD in patients

8:00-9:30 am

Neuro Workshop/Vaccine Safety
0180-0000-09-113-L01-P
Speakers: Lizbeth Hansen, PharmD, Pediatric Care Specialist
Cleveland Clinic
Johanna Goldfarb, PharmD, Head, Pediatric Infectious Diseases
Cleveland Clinic Children's Hospital

By the end of this presentation, participants will be able to:

1. Examine the literature describing the pharmacokinetics and pharmacodynamics of drugs used concomitantly with therapeutic hypothermia.
2. Discuss clinical examples of these "interactions" and their significance in patient care.
3. Review the history of vaccine development and safety in the U.S.
4. Review data on claims of vaccine side effects and present system in the U.S. for compensation.

8:00-9:30 am

Oncology Workshop
0180-0000-09-114-L01-P
Speaker: William Humphrey, PharmD, Director, Pharmacy Operations
St. Jude Children's Research Hospital

By the end of this presentation, participants will be able to:

1. Describe areas to consider when developing a chemotherapy safety program.
2. Name ways to minimize occupational exposure in preparation and administration of antineoplastic chemotherapy.
3. Identify means for ensuring patient safety with chemotherapy including manual and electronic checks and balances.

9:40-11:40 am

Super Session: Hot Topics
0180-0000-09-124-L04-P
Speakers: Jeff Cies, PharmD, Pharmacy Clinical Coordinator and Critical Care Clinical Pharmacist
St. Christopher's Hospital for Children
Betsy Walters

By the end of this presentation, participants will be able to:

1. Identify recent developments in the field of pediatric critical care and their impact to clinical practice.
2. Summarize recent developments in the field of pediatric infectious diseases and their impact to clinical practice.
3. Describe the changes for Synagis® administration for at-risk infants based on new guidelines.
4. Understand the new vitamin D guidelines including RDA for infants and children.
5. Determine when repeat courses of antenatal steroids could be used in at-risk patients.

